Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, explains recommendations for annual mammography screenings after COVID-19 vaccination and why guidelines differ for diagnostic visits.
Because lymph nodes tend to swell, women should wait at least 6 weeks when scheduling a screening mammogram after COVID-19 vaccination; however, diagnostic visits for lumps should not wait, emphasized Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
Transcript
Is there an optimal waiting period between COVID-19 vaccination or booster dosing and scheduling either a mammogram or an annual gynecological visit?
If someone has a screening mammogram—meaning that they don’t have any symptoms, but they’re just getting their routine annual screen—then, on average, they should probably wait about 6 weeks after they get a vaccination for coronavirus.
The reason for this is because sometimes when you get a vaccination, it can cause lymph nodes in the armpit or the axilla to become enlarged. There’s nothing wrong with them, it’s just a natural result of having a vaccination in your arm that is stimulating your immune system. Your lymph nodes are kind of doing what they’re supposed to be doing. They respond to it, and whenever we see that happen, which is common, it usually resolves after about 6 weeks. So we think if people are getting a screening mammogram, then they should probably wait about 6 weeks after COVID-19 vaccination.
That’s different, though, than women who are getting a diagnostic mammogram. If you have a mass in your breast, you should not delay in getting it worked up. And there’s really not an issue with cervical cancer screening and the timing of vaccination.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More